Viridian Therapeutics (NASDAQ:VRDN) Receives “Buy” Rating from Needham & Company LLC

Viridian Therapeutics (NASDAQ:VRDN)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports. They presently have a $30.00 target price on the stock. Needham & Company LLC’s price target suggests a potential upside of 101.34% from the company’s current price.

VRDN has been the subject of several other research reports. B. Riley downgraded Viridian Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $25.00 to $20.00 in a research note on Thursday. Wedbush upped their price objective on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.10.

Viridian Therapeutics Price Performance

VRDN stock opened at $14.90 on Thursday. The company’s 50-day moving average price is $16.46 and its two-hundred day moving average price is $17.64. The firm has a market cap of $950.92 million, a P/E ratio of -2.80 and a beta of 1.14. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09. Viridian Therapeutics has a 12 month low of $10.93 and a 12 month high of $28.35.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the firm posted ($1.61) earnings per share. The firm’s quarterly revenue was down 26.5% compared to the same quarter last year. On average, analysts anticipate that Viridian Therapeutics will post -4.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently modified their holdings of VRDN. Vestal Point Capital LP acquired a new stake in Viridian Therapeutics in the fourth quarter valued at $21,780,000. Perceptive Advisors LLC grew its position in shares of Viridian Therapeutics by 71.1% in the 4th quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after buying an additional 719,007 shares during the last quarter. RTW Investments LP acquired a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $13,195,000. Braidwell LP lifted its stake in shares of Viridian Therapeutics by 43.8% in the third quarter. Braidwell LP now owns 1,735,182 shares of the company’s stock worth $26,618,000 after acquiring an additional 528,882 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Viridian Therapeutics by 170.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 313,217 shares of the company’s stock valued at $4,805,000 after acquiring an additional 197,430 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.